RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at protein expression in tumor tissue samples from patients with stage II or stage III rectal cancer enrolled in clinical trial SWOG-9304.
OBJECTIVES: * Determine expression levels of thioredoxin-1 (Trx-1), thioredoxin-interacting protein (TXNIP), and hypoxia inducible factor-1 alpha (HIF-1α) in paraffin-embedded resected tumor tissue samples from patients with stage II or III rectal cancer enrolled in clinical trial SWOG-9304. * Determine if there is a correlation between Trx-1 and TXNIP expression and HIF-1α expression. * Correlate expression of these proteins with tumor stage, disease-free survival, overall survival, and risk of recurrence. * Determine interactions for patient age, performance status, and type of therapy received on clinical trial SWOG-9304. OUTLINE: This is a multicenter study. Paraffin-embedded resected tumor tissue samples are analyzed for protein expression levels (thioredoxin-1, thioredoxin-interacting protein, and hypoxia inducible factor-1 alpha) by tissue microarray and immunostaining.
Study Type
OBSERVATIONAL
Enrollment
220
Expression of thioredoxin-1, thioredoxin-interacting protein, and hypoxia inducible factor-1 alpha
Time frame: upon testing of specimens
Correlation of expression of these proteins with tumor stage, disease-free survival, overall survival, and risk of recurrence
Time frame: upon provision of expression to Statistical Center
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.